Search results
30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
We enrolled 654 patients in the BRAVE-AA1 trial and 546 in...
- Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith
A 53-year-old landscaper presented with a 4-month history of...
- Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay
Notwithstanding ongoing confusion over the concepts of...
- Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes
Nonspecific low back pain is diagnosed by ruling out other...
- Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries
Scalp hair regrowth is associated with improvements in...
- Clinical Problem-Solving Looking Back L. Glick and Others
On examination, the temperature was 36.1°C, the blood...
- Correspondence Dec 15, 2022 Ivermectin Treatment for Covid-19
Reis G, Silva EASM, Silva DCM, et al. Effect of early...
- Editorial Audio Interview
In this audio interview conducted on May 2, 2022, the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
28 cze 2021 · Well-designed RCTs with longer treatment and higher doses are necessary to further evaluate the safety of IVM in patients with COVID-19. Our study has several strengths. First, we performed a recent and comprehensive systematic search in 5 engines and unpublished studies without language restriction.
1 sie 2024 · Total ivermectin non-high doses ranged from 12 to 43 mg, and total high doses ranged from 63 to 420 mg; treatment durations varied from a single dose to 6 days. The controls were placebo in nine RCTs, SoC in two RCTs, and placebo or active drug in one RCT.
26 lip 2021 · Further, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of Ivermectin. 9 A dose of 12 mg twice daily alone or in combination with other therapy for 5–7 days has been proposed as a safe therapeutic option for mild, moderate or severe cases of Covid-19 ...
Table. Evidence-base interventions for COVID-19 patients not requiring hospitalisation. Disease severity classification as per the Ministry of Health and Family Welfare, Government of India. PPE=personal protective equipment. SpO 2 =oxygen saturation. * Patients with mild symptoms and SpO 2 ≥94%. †. Patients with SpO 2 <94 and ≥90.
Methods: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1st August and 31st October 2020.
30 mar 2022 · Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 μg per kilogram of body...
